Figure 4
From: A fully caninised anti-NGF monoclonal antibody for pain relief in dogs
Pharmacokinetic profile of NV-01 in the dog. A) Single dose. NV-01 (2 mg/kg) was infused intravenously and the NV-01 serum concentration assayed by ELISA over a period of 14 days. B) Repeat dosing in two dogs. NV-01 (2 mg/kg) was administered by intravenous infusion twice, with a gap of eight months between each dose. The NV-01 concentration was determined by ELISA in serum samples taken over a period of 7 days after each infusion.